表紙
市場調查報告書

數位生物標記的全球市場:分析與預測 (2019-2025年)

Global Digital Biomarkers Market: Focus on Key Trends, Growth Potential, Competitive Landscape, Components, End Users, Application and Region - Analysis and Forecast, 2019-2025

出版商 BIS Research Inc. 商品編碼 919278
出版日期 內容資訊 英文 273 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
數位生物標記的全球市場:分析與預測 (2019-2025年) Global Digital Biomarkers Market: Focus on Key Trends, Growth Potential, Competitive Landscape, Components, End Users, Application and Region - Analysis and Forecast, 2019-2025
出版日期: 2019年12月11日內容資訊: 英文 273 Pages
簡介

全球數位生物標記市場規模在2019年∼2025年的預測期間內,預計將以40.39%的年複合成長率 (CAGR) 發展。

本報告涵括全球數位生物標記市場,提供市場動態,競爭環境,各市場區隔、地區的市場,競爭情形,及主要企業等相關之詳細分析。

摘要整理

第1章 調查範圍、手法

  • 調查範圍
  • 調查手法

第2章 數位生物標記:全球展望

  • 定義
  • 數位生物標記的現狀
  • 數位生物標記的生態系統
  • 資料檢測
  • 生物標記的種類
  • 產業
  • 數位生物標記:技術形勢
  • 成功案例的案例研究:主要的治療領域

第3章 市場動態

  • 成長促進因素
  • 市場課題
  • 市場機會

第4章 競爭情形

  • 概要
  • 主要的發展、策略
  • 競爭基準

第5章 數位生物標記市場機會、成長率

  • 資料收集
    • 穿戴式設備
    • 嵌入式零組件/感測器
    • 行動/平板電腦用途
    • 平台
    • 桌上型軟體
  • 資料整合
    • 市場估計、預測
    • 競爭情形

第6章 全球數位生物標記市場:各用途

  • 睡眠、運動
  • 心血管
  • 心情、行動
  • 疼痛管理
  • 神經退化性疾病
  • 呼吸狀態

第7章 全球數位生物標記市場:各終端用戶

  • 生物醫藥品企業
  • 保險者
  • 提供者

第8章 全球數位生物標記市場:各地區

  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 其他 (RoW)

第9章 企業簡介

  • 概要
  • ActiGraph, LLC.
  • Akili Interactive Labs
  • AliveCor Inc.
  • Altoida Inc.
  • Amgen Inc
  • Bayer AG
  • Biogen Inc
  • Eli Lilly and Company
  • Evidation Health, Inc
  • Fitbit, Inc.
  • GlaxoSmithKline Plc
  • Human API
  • Happify Health
  • IXICO Plc
  • Neurotrack Technology, Inc
  • Novartis
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Sanofi
  • 武田藥品工業
  • Verily Life Science LLC
目錄
Product Code: BH174A

Global Digital Biomarkers Market to Grow at a CAGR of 40.39% from 2019-2025.

Key Questions Answered in the Report:

  • What is the total addressable market (TAM) and the potential market opportunity for the global digital biomarkers market?
  • What are the major market drivers and challenges of, and the opportunities in, the global digital biomarkers market?
  • What is the market share of the leading segments and sub-segments of the global digital biomarkers market in 2019 and 2025?
  • How did the global digital biomarkers market evolve?
  • How is each segment of the global digital biomarkers market expected to grow during the forecast period and what is the expected revenue to be generated by each of the segments by the end of 2025?
  • What are the consumer preferences in terms of adoption of wearable technology for the assessment of medical conditions?
  • What are the key developmental strategies implemented by the key players to stand out in this market?
  • What is the preferred business model used for building digital biomarkers?
  • Which area of application is expected to be the highest revenue generator in the global digital biomarkers market during the forecast period?
  • Which end user segment is expected to be the highest revenue generator in this industry during the forecast period?
  • What is the potential of global digital biomarkers market in the emerging countries during the forecast period?

Global Digital Biomarkers Market Forecast, 2019-2025

The Global Digital Biomarkers Market Report by BIS Research projects the market to grow at a significant CAGR of 40.39% during the forecast period from 2019 to 2025. There are multiple factors that drive the market, such as the surge in the demand for mobile health apps and consumer wearable technology specifically for tracking health. For instance, as of 2019, about 35% of the U.S. adult population (18 to 29 years) track their health with the help of mobile apps while 27% of the adults own and use a wearable device for monitoring heart rate, blood pressure, physical activity, or other vitals.

Furthermore, the data generated from wearable devices are increasingly being validated through studies based on clinical trials. For instance, the number of clinical trials conducted using wearable devices was consistent during the period of 2008 to 2018, i.e. 5-12 trials annually. However, the number surged significantly in 2016 and 2017, with 27 and 32 trials (using mobile devices) commencing each year respectively. The primary reason for this rise in such trials in 2016 and 2017 can be attributed to the considerable surge in the sponsorship for these studies.

Expert Quote

"Cardiovascular disease segment is currently the largest therapeutic segment for the global digital biomarkers market and holds a share of 31.75% of the market, followed by neurodegenerative diseases with a share of 20.63%. During the forecast period, pain management, and mood and behavior segments, are expected to witness the highest CAGR of 59.07% and 45.34%, respectively. The growth in the pain management segment is primarily due to increasing development and adoption of AR/VR solutions for the detection and treatment of chronic pain."

Scope of the Market Intelligence on Global Digital Biomarkers Market

The purpose of this study is to gain a holistic view of the global digital biomarkers market in terms of various influencing factors such as regional adoption trends, technological advancements, and pricing patterns.

The scope of this report constitutes an in-depth study of the global digital biomarkers market, including a thorough analysis of the products in the market as well as their adoption spanning different regions. The market has been chiefly segmented into component, application, end user, and region. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.

Market Segmentation

The Global Digital Biomarkers Market can be segmented on the basis of component type, application, end user, and region. As of 2018, biopharma companies held an estimated 57% of the global digital biomarkers market. Numerous collaborations and partnerships were witnessed in 2017 and 2018, aimed at developing digital solutions for the clinical assessment various disorders such as cardiovascular, neurodegenerative, and respiratory. Some of the notable biopharma companies engaging in partnership activities include, Takeda, Biogen, and Sanofi among others. A significant contribution was also witnessed from healthcare providers, who held an estimated 42% of the global digital biomarkers market in 2018.

During the forecast period (2019-2025), the health insurance payers are expected to evolve as the largest end user segmented in the global digital biomarkers market. The growth rate for this segment is expected to be 44.04% during the forecast period. This high growth rate is primarily due to an increasing use of digital biomarkers by payer groups to effectively devise individualized care plans.

In terms of region, Asia-Pacific is the largest market in the digital biomarkers space and is expected to remain same during the forecast period. North America is also contributing to the growth of this space. The elevated level of smartphone and wearable technology in these regions as well as the high incidence of lifestyle-related diseases are pushing consumers in the region to monitor their medical conditions.

However, during the forecast period, Europe is expected to attain the highest CAGR of 41.99%. The growth is primarily due to increasing standardization and collaboration among key stakeholders in the industry.

Key Companies in the Global Digital Biomarkers Market

Some of the major key players in the global digital biomarkers market include ActiGraph, LLC., Akili Interactive Labs, AliveCor, Inc., Fitbit, Inc., HumanAPI, Novartis, Pfizer Inc. F. Hoffmann-La Roche Ltd, Sanofi, Takeda Pharmaceuticals, and Verily Life Science LLC.

Table of Contents

Executive Summary

1. Research Scope and Methodology

  • 1.1. Research Scope
  • 1.2. Global Digital Biomarkers Market: Research Methodology
    • 1.2.1. Primary Data Sources
    • 1.2.2. Secondary Data Sources

2. Digital Biomarkers: Global Perspective

  • 2.1. Definition
  • 2.2. Current State of Digital Biomarkers
  • 2.3. Digital Biomarkers Ecosystem
    • 2.3.1. Digital Platforms
      • 2.3.1.1. Wearables Devices
      • 2.3.1.2. Implantable Components/Sensors
      • 2.3.1.3. Ingestible Sensors
      • 2.3.1.4. Ocular Devices
      • 2.3.1.5. Accelerometers
      • 2.3.1.6. Smart Home Systems/IOTs
      • 2.3.1.7. AR/VR Platforms
      • 2.3.1.8. Desktop/Web Apps
  • 2.4. Data Measurements
    • 2.4.1. Physiological Parameters
    • 2.4.2. Behavioral Parameters
  • 2.5. Types of Biomarkers
    • 2.5.1. Wellness
    • 2.5.2. Disease
    • 2.5.3. Drugs
  • 2.6. Industry
    • 2.6.1. Pharmaceutical
    • 2.6.2. Biotechnology/Life Sciences
    • 2.6.3. Medical Devices
    • 2.6.4. App Vendors
    • 2.6.5. Clinical Trials (Clinical Research Organizations)
    • 2.6.6. Technology Vendors
  • 2.7. Digital Biomarkers: Technology Landscape
    • 2.7.1. Artificial Intelligence and Machine Learning
    • 2.7.2. Augmented Reality and Virtual Reality
    • 2.7.3. Blockchain
    • 2.7.4. Edge Computing
    • 2.7.5. Cloud Computing
  • 2.8. Successful Case Studies: Key Therapeutic Areas
    • 2.8.1. Cardiovascular Disease
    • 2.8.2. Parkinson's Disease
    • 2.8.3. Alzheimer's Disease
    • 2.8.4. Huntington's disease

3. Market Dynamics

  • 3.1. Growth Promoting Factors
    • 3.1.1. Increasing Cost of Drug Development
    • 3.1.2. Failure for Drugs for Neurodegenerative Disorder
    • 3.1.3. Regulatory Flexibility Toward Digital Health Solutions
    • 3.1.4. Explosion of Wearable Devices and Increasing Smartphone Penetration
  • 3.2. Market Challenges
    • 3.2.1. Test and Validation
    • 3.2.2. Addressing Biases
    • 3.2.3. Validation Testing
    • 3.2.4. Integration
    • 3.2.5. Cost and Usability
  • 3.3. Market Opportunities
    • 3.3.1. Personalized Medicine
    • 3.3.2. Investment in Voice-Based Digital Biomarkers
    • 3.3.3. Investment in Wearable Technology
      • 3.3.3.1. Early Detection of Neurological Disorders
      • 3.3.3.2. For General Health Management
      • 3.3.3.3. Metabolic, Cardiovascular, and Gastrointestinal Health
      • 3.3.3.4. Maternal, Pre- and Neo-Natal Care
      • 3.3.3.5. Pulmonary Health and Environmental Exposures

4. Competitive Landscape

  • 4.1. Key Strategies and Developments
    • 4.1.1. Synergistic Interactions
    • 4.1.2. Product Launches and Enhancements
    • 4.1.3. Business Expansion and Funding Activities
    • 4.1.4. Acquisitions, Approvals, and Others

5. Digital Biomarker Market Opportunities and Growth, 2018-2025 ($Million)

  • 5.1. Data Collection (Sensors and Tools that Collect Data)
    • 5.1.1. Wearables Devices
      • 5.1.1.1. Market Estimation and Forecast, 2018-2025
      • 5.1.1.2. Opportunity in Digital Biomarker
      • 5.1.1.3. New Developments
      • 5.1.1.4. Competitive Landscape
    • 5.1.2. Implantable Components/Sensors
      • 5.1.2.1. Market Estimation and Forecast, 2018-2025
      • 5.1.2.2. Opportunity in Digital Biomarker
      • 5.1.2.3. New Developments
      • 5.1.2.4. Competitive Landscape
    • 5.1.3. Mobile/Tablet Apps
      • 5.1.3.1. Market Estimation and Forecast, 2018-2025
      • 5.1.3.2. Opportunity in Digital Biomarker
      • 5.1.3.3. New Developments
      • 5.1.3.4. Competitive Landscape
    • 5.1.4. Platforms
      • 5.1.4.1. Market Estimation and Forecast, 2018-2025
      • 5.1.4.2. Opportunity in Digital Biomarker
      • 5.1.4.3. Competitive Landscape
    • 5.1.5. Desktop Based Software
      • 5.1.5.1. Market Estimation and Forecast, 2018-2025
      • 5.1.5.2. New Developments
      • 5.1.5.3. Competitive Landscape
  • 5.2. Data Integration (Systems that Integrate Data)
    • 5.2.1. Market Estimation and Forecast, 2018-2025
    • 5.2.2. Competitive Landscape

6. Global Digital biomarkers Market (by Application)

  • 6.1. Sleep and Movement
  • 6.2. Cardiovascular
  • 6.3. Mood and Behavior
  • 6.4. Pain Management
  • 6.5. Neurodegenerative Disorders
  • 6.6. Respiratory Conditions

7. Global Digital Biomarkers Market, by End Users

  • 7.1. Biopharmaceutical Companies
    • 7.1.1. Role of Biopharma Companies in the Development of Digital Biomarkers
    • 7.1.2. Major Therapeutic Areas for Biomarkers
      • 7.1.2.1. Respiratory Diseases
      • 7.1.2.2. Neurodegenerative Diseases
      • 7.1.2.3. Cardiovascular Diseases
      • 7.1.2.4. Diabetes
  • 7.2. Payers
  • 7.3. Providers

8. Global Digital Biomarkers Market (by Region)

  • 8.1. North America
    • 8.1.1. U.S
      • 8.1.1.1. Digital Health Scenario
      • 8.1.1.2. Degree of Adoption of Wearables
      • 8.1.1.3. Degree of Adoption of Mobile Health Applications
      • 8.1.1.4. Local Players in the Digital Biomarker Market
      • 8.1.1.5. Regulatory Scenario
    • 8.1.2. Canada
      • 8.1.2.1. Digital Health Scenario
      • 8.1.2.2. Degree of Adoption of Wearables
      • 8.1.2.3. Degree of Adoption of Mobile Health Applications Adoption
      • 8.1.2.4. Local Digital Biomarker Market
      • 8.1.2.5. Regulatory Scenario
      • 8.1.2.6. Future of Digital Health in Canada
  • 8.2. Europe
    • 8.2.1. Netherlands
      • 8.2.1.1. Digital Health Scenario
      • 8.2.1.2. Level of Wearables Adoption
      • 8.2.1.3. Degree of Adoption of Mobile Health Applications
      • 8.2.1.4. Local Players in the Digital Biomarker Market
    • 8.2.2. Germany
      • 8.2.2.1. Digital Health Scenario
      • 8.2.2.2. Degree of Adoption of Wearables
      • 8.2.2.3. Reluctance to Fitness Trackers
      • 8.2.2.4. Future of Digital Health in Germany
    • 8.2.3. U.K.
      • 8.2.3.1. Digital Health Scenario
      • 8.2.3.2. Degree of Adoption of Wearables
      • 8.2.3.3. Increasing Sales of Smart Watches
      • 8.2.3.4. Abandonment of Wearables
      • 8.2.3.5. Local Players in Wearables
    • 8.2.4. France
      • 8.2.4.1. Digital Health Scenario
      • 8.2.4.2. Degree of Wearables Adoption
      • 8.2.4.3. Local Players in Digital Biomarkers Market
    • 8.2.5. Spain
      • 8.2.5.1. Digital Health Scenario
      • 8.2.5.2. Degree of Adoption of Wearables
    • 8.2.6. Italy
      • 8.2.6.1. Digital Health Scenario
      • 8.2.6.2. Degree of Adoption of Wearables

8.2.6.2.1. Degree of Adoption of Mobile Health Applications

    • 8.2.7. Russia
      • 8.2.7.1. Digital Health Scenario
      • 8.2.7.2. Degree of Adoption of Wearables
      • 8.2.7.3. Degree of Adoption of Mobile Health Applications
    • 8.2.8. Rest-of-Europe
      • 8.2.8.1. Digital Health Scenario
      • 8.2.8.2. Degree of Adoption of Wearables
      • 8.2.8.3. Degree of Adoption of Mobile Health Applications
      • 8.2.8.4. Local Player in Digital Biomarker Market
  • 8.3. Asia-Pacific
    • 8.3.1. China
      • 8.3.1.1. Digital Health Scenario
      • 8.3.1.2. Degree of Adoption of Wearables
      • 8.3.1.3. Degree of Adoption of Mobile Health Applications
      • 8.3.1.4. Local Players in Digital Biomarker Market
    • 8.3.2. Japan
      • 8.3.2.1. Digital Health Scenario
      • 8.3.2.2. Degree of Wearables Adoption
      • 8.3.2.3. Degree of Mobile Health Applications Adoption
      • 8.3.2.4. Local Players in Digital Biomarker Market
    • 8.3.3. South Korea
      • 8.3.3.1. Digital Health Scenario
      • 8.3.3.2. Degree of Adoption of Wearables
      • 8.3.3.3. Degree of Adoption of Mobile Health Applications
    • 8.3.4. India
      • 8.3.4.1. Digital Health Scenario
      • 8.3.4.2. Degree of Adoption of Wearables
      • 8.3.4.3. Degree of adoption of Mobile Health Applications
      • 8.3.4.4. Local Players in Digital Biomarker Market
    • 8.3.5. Australia
      • 8.3.5.1. Digital Health Scenario
      • 8.3.5.2. Level of Wearables Adoption
      • 8.3.5.3. Level of Mobile Health Applications Adoption
    • 8.3.6. Singapore
      • 8.3.6.1. Digital Health Scenario
      • 8.3.6.2. Degree of Adoption of Wearables
      • 8.3.6.3. Degree of Adoption of Mobile Health Applications
    • 8.3.7. Rest-of-Asia-Pacific
      • 8.3.7.1. Digital Health Scenario
      • 8.3.7.2. Degree of adoption of Wearables and Mobile Health Application
  • 8.4. Latin America
    • 8.4.1. Brazil
      • 8.4.1.1. Digital Health Scenario
      • 8.4.1.2. Degree of Adoption of Wearables
      • 8.4.1.3. Degree of Adoption of Mobile Health Applications
    • 8.4.2. Mexico
      • 8.4.2.1. Digital Health Scenario
      • 8.4.2.2. Degree of Adoption of Wearables
      • 8.4.2.3. Degree of Adoption of Mobile Health Applications
  • 8.5. Rest-of-the-World
    • 8.5.1. Saudi Arabia
      • 8.5.1.1. Digital Health Scenario
      • 8.5.1.2. Degree of Adoption of Wearables
      • 8.5.1.3. Degree of Adoption of Mobile Health Applications
    • 8.5.2. UAE
      • 8.5.2.1. Digital Health Scenario
      • 8.5.2.2. Degree of Adoption of Wearables and Mobile Health Applications
    • 8.5.3. Israel
      • 8.5.3.1. Digital Health Scenario
      • 8.5.3.2. Degree of Adoption of Wearables
    • 8.5.4. South Africa
      • 8.5.4.1. Digital Health Scenario
      • 8.5.4.2. Degree of Adoption of Wearables
      • 8.5.4.3. Degree of Adoption of Mobile Health Applications

9. Company Profiles

  • 9.1. Overview
  • 9.2. ActiGraph, LLC.
    • 9.2.1. Company Overview
    • 9.2.2. Role of ActiGraph, LLC. In Global Digital Biomarkers Market
    • 9.2.3. Product Offerings
    • 9.2.4. Recent Developments
    • 9.2.5. SWOT Analysis: ActiGraph, LLC.
  • 9.3. Akili Interactive Labs
    • 9.3.1. Company Overview
    • 9.3.2. Role of Akili Interactive Labs in the Global Digital Biomarkers Market
    • 9.3.3. Product Portfolio
    • 9.3.4. Recent Developments
    • 9.3.5. SWOT Analysis
  • 9.4. AliveCor Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Role of AliveCor, Inc. in the Global Digital Biomarkers Market
    • 9.4.3. Product Description
    • 9.4.4. Recent Development
    • 9.4.5. SWOT Analysis
  • 9.5. Altoida Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Role of Altoida Inc. in Global Digital Biomarkers Market
    • 9.5.3. Product Profiling
    • 9.5.4. Key Developments
    • 9.5.5. SWOT Analysis
  • 9.6. Amgen Inc
    • 9.6.1. Company Overview
    • 9.6.2. Amgen's Role in Global Digital Biomarkers Market.
    • 9.6.3. Financials
    • 9.6.4. Key Insights about Financial Health of the Company
    • 9.6.5. SWOT Analysis
  • 9.7. Bayer AG
    • 9.7.1. Company Overview
    • 9.7.2. Role of Bayer Inc. in the Global Digital Biomarkers Market
    • 9.7.3. Financials
    • 9.7.4. Key Insights about Financial Health of the Company
    • 9.7.5. SWOT Analysis
  • 9.8. Biogen Inc
    • 9.8.1. Company Overview
    • 9.8.2. Role of Biogen Inc in Global Digital Biomarkers Market
    • 9.8.3. Financials
    • 9.8.4. Key Insights about Financial Health of the Company
    • 9.8.5. SWOT Analysis
  • 9.9. Eli Lilly and Company
    • 9.9.1. Company Overview
    • 9.9.2. Role of Eli Lilly in Global Digital Biomarkers Market
    • 9.9.3. Financials
    • 9.9.4. Key Insights about Financial Health of the Company
    • 9.9.5. SWOT Analysis
  • 9.10 Evidation Health, Inc
    • 9.10.1. Company Overview
    • 9.10.2. Role of Evidation Health in Global Digital Biomarker Market
    • 9.10.3. Product Offerings
    • 9.10.4. Recent Developments
    • 9.10.5. SWOT Analysis
  • 9.11 Fitbit, Inc.
    • 9.11.1. Company Overview
    • 9.11.2. Role of Fitbit Inc. in Global Digital Biomarker Market.
    • 9.11.3. Recent Developments
    • 9.11.4. Product Offerings
    • 9.11.5. Financials
    • 9.11.6. Key Insights about Financial Health of the Company
    • 9.11.7. SWOT Analysis
  • 9.12 GlaxoSmithKline Plc
    • 9.12.1. Company Overview
    • 9.12.2. Role of GlaxoSmithKline in Global Digital Biomarkers Market
    • 9.12.3. Financials
    • 9.12.4. SWOT Analysis
  • 9.13 Human API
    • 9.13.1. Company Overview
    • 9.13.2. Role of Human API in Global Digital Biomarkers market.
    • 9.13.3. Human API: Product Offering
    • 9.13.4. Key Developments
    • 9.13.5. SWOT Analysis
  • 9.14 Happify Health
    • 9.14.1. Company Overview
    • 9.14.2. Role of Happify Health in Global Digital Biomarker Market
    • 9.14.3. Happify: Product Offerings
    • 9.14.4. Happify: Recent Developments
    • 9.14.5. SWOT Analysis
  • 9.15 IXICO Plc
    • 9.15.1. Company Overview
    • 9.15.2. Role of IXICO plc in the Global Digital Biomarkers Market
    • 9.15.3. Product Offerings
    • 9.15.4. Financials
    • 9.15.5. Key Insights about Financial Health of the Company
    • 9.15.6. SWOT Analysis
  • 9.16 Neurotrack Technology, Inc
    • 9.16.1. Company Overview
    • 9.16.2. Role of Neurotrack Technology, Inc in Global Digital Biomarker Market
    • 9.16.3. Neurotrack Technology: Product Offering
    • 9.16.4. Neurotrack Technology: Recent Developments
    • 9.16.5. SWOT Analysis
  • 9.17 Novartis
    • 9.17.1. Company Overview
    • 9.17.2. Role of Novartis AG in the Global Digital Biomarkers Market
    • 9.17.3. Financials
    • 9.17.4. Key Insights about Financial Health of the Company
    • 9.17.5. SWOT Analysis
  • 9.18 Pfizer Inc.
    • 9.18.1. Company Overview
    • 9.18.2. Role of Pfizer Inc in the Global Digital Biomarkers Market
    • 9.18.3. Product Offerings
    • 9.18.4. Recent Developments of Pfizer Inc in Global Digital Biomarkers Market
    • 9.18.5. Financials
    • 9.18.6. Key Insights about Financial Health of the Company
    • 9.18.7. SWOT Analysis
  • 9.19 F. Hoffmann-La Roche Ltd
    • 9.19.1. Company Overview
    • 9.19.2. Role of F. Hoffmann-La Roche Ltd in the Global Digital Biomarkers Market
    • 9.19.3. Financials
    • 9.19.4. Key Insights about Financial Health of the Company
    • 9.19.5. SWOT Analysis
  • 9.20 Sanofi
    • 9.20.1. Company Overview
    • 9.20.2. Role of Sanofi in Global Digital Biomarker Market
    • 9.20.3. Financials
    • 9.20.4. SWOT Analysis
  • 9.21 Takeda Pharmaceuticals
    • 9.21.1. Company Profile
    • 9.21.2. Role of Takeda Pharmaceuticals in the Global Digital Biomarkers Market
    • 9.21.3. Financials
    • 9.21.4. Key Insights about Financial Health of the Company
    • 9.21.5. SWOT Analysis
  • 9.22 Verily Life Science LLC
    • 9.22.1. Company Overview
    • 9.22.2. Role of Verily Life Science LLC in Global Digital Biomarkers Market
    • 9.22.3. Product Offerings
    • 9.22.4. Recent Developments
    • 9.22.5. SWOT Analysis: Verily Life Science LLC Life Sciences

List of Tables

  • Table 1: A Comparison Between Examples of Clinical Biomarkers and Digital Biomarkers
  • Table 2: Percentage of Different Wearable Technology Brands being Used in Clinical Trials (2018)
  • Table 2.1: Different Categories of Mobile Health Applications
  • Table 3.1: Major FDA Clearances in 2019
  • Table 3.2: Leading Wearable Devices and their Features
  • Table 4.1: Synergistic Activities Share (by Company), January 2016 - September 2019
  • Table 4.2: Product Launches and Enhancements Share (by Company), January 2016 - September 2019
  • Table 4.3: Business Expansion and Funding Activities Share (by Company), January 2016 - September 2019
  • Table 4.4: Key Acquisitions in the global digital biomarkers Space (2019)
  • Table 6.1: Leading Respiratory Conditions and Related Deaths
  • Table 8.1: Different Types of Health Tracking People and Their Characteristics
  • Table 8.2: Different Wearables and Their Adoption Rates in Australia
  • Table 8.3: Different Wearables and Their Expected Adoption Rates in Australia
  • Table 8.4: Different Wearables and Their Adoption Rates in Singapore
  • Table 8.5: Different Wearables and Their Expected Adoption Rates in Singapore
  • Table 8.6: Different Wearables and Their Adoption Rates in Mexico
  • Table 8.7: Different Wearables and Their Expected Adoption Rates in Singapore

List of Figures

  • Figure 1: Global Subscriber Base and Smartphone Penetration
  • Figure 2: Number of Trials that Commenced Each Year using Wearable Technology
  • Figure 3: Percentage of Completed and Active Clinical Trials Using Wearables
  • Figure 4: Global Digital Biomarkers Market, by Type (2018-2025)
  • Figure 5: Global Digital Biomarkers Market, Provider Type: Data Collection (2018-2025)
  • Figure 6: Global Digital Biomarkers Market, Data Collection System Type (2018-2025)
  • Figure 7: Global Digital Biomarkers Market, Data Integration System Providers (2018-2025)
  • Figure 8: Global Digital Biomarkers Market, by Application/Therapeutic Area (2018-2025)
  • Figure 9: Share of Leading Therapeutic Areas in the Digital Biomarkers Market
  • Figure 10: Global Digital Biomarkers Market, by End Users (2018-2025)
  • Figure 11: Current Penetration of Different End User Groups in the Digital Biomarkers Market (2018)
  • Figure 12: Global Digital Biomarkers Market, by Region (2018-2025)
  • Figure 1.1: Global Digital Biomarkers Market Segmentation
  • Figure 1.2: Global Digital Biomarkers Market Research Methodology
  • Figure 1.3: Primary Research
  • Figure 1.4: Secondary Research
  • Figure 1.5: Data Triangulation
  • Figure 1.6: Bottom-up Approach (Segment-wise Analysis)
  • Figure 1.7: Top-down Approach (Segment-wise Analysis)
  • Figure 1.8: Assumptions and Limitations
  • Figure 1.9: Considered Factors for Data Prediction and Modeling
  • Figure 1.10: Scope Definition for the Global Digital Biomarkers Market
  • Figure 2.1: Major Components of Digital Biomarkers Market
  • Figure 2.2: A flowchart depicting the conversion of healthcare data to a digital biomarker
  • Figure 2.3: Different Populations of Data Producers of Digital Biomarkers
  • Figure 3.1: Failure rate of different phase II drugs
  • Figure 3.2: Rising Research and Development (R&D) Cost of the FDA Cleared Drugs.
  • Figure 3.3: Number of Alzheimer's Disease Drug no Longer Under Development
  • Figure 4.1: Share of Key Developments and Strategies, January 2016 - September 2019
  • Figure 5.1: Global Digital Biomarker Data Collection Market, 2018-2025
  • Figure 5.2: Global Wearable Devices Market, 2018-2025
  • Figure 5.3: Global Implantable Components/Biosensors Market, 2018-2025
  • Figure 5.4: Global Mobile/Tablet Apps Market, 2018-2025
  • Figure 5.5: Global Platform Market, 2018-2025
  • Figure 5.6: Global Desktop Based Software Market, 2018-2025
  • Figure 5.7: Global Data Integration Systems Market, 2018-2025
  • Figure 6.1: Global Digital Biomarkers Market, Application Type: Sleep and Movement, 2018-2025
  • Figure 6.2: Global Digital Biomarkers Market, Application Type: Cardiovascular, 2018-2025
  • Figure 6.3: Global Digital Biomarkers Market, Application Type: Mood and Behaviour, 2018-2025
  • Figure 6.4: Global Digital Biomarkers Market, Application Type: Pain Management, 2018-2025
  • Figure 6.5: Global Digital Biomarkers Market, Application Type: Neurodegenerative Disorders, 2018-2025
  • Figure 6.6: Disease burden in the U.S. (by Therapeutic Area)
  • Figure 6.7: Global Digital Biomarkers Market, Application Type: Respiratory Conditions, 2018-2025
  • Figure 7.1: Potential Use Cases of Digital Biomarkers (From an End User Perspective)
  • Figure 7.2: Global Digital Biomarkers Market, End User Type: Biopharma companies, 2018-2025
  • Figure 7.3: Global Digital Biomarkers Market, End User Type: Health Insurance Payers, 2018-2025
  • Figure 7.4: Global Digital Biomarkers Market, End User Type: Healthcare Providers, 2018-2025
  • Figure 8.1: North America Digital Biomarkers Market, 2018-2025
  • Figure 8.2: Factors Influencing Digital Biomarkers Market in North America
  • Figure 8.3: U.S. Digital Biomarkers Market, 2018-2025
  • Figure 8.4: U.S. Digital Biomarkers Market (by Setting), 2018-2025
  • Figure 8.5: Canada Digital Biomarkers Market, 2018-2025
  • Figure 8.6: Canada Digital Biomarkers Market (by Setting), 2018-2025
  • Figure 8.7: Mobile Health Applications: Usage Areas
  • Figure 8.8: Europe Digital Biomarkers Market, 2018-2025
  • Figure 8.9: Factors Influencing Digital Biomarkers Market in Europe
  • Figure 8.10: Netherlands Digital Biomarkers Market, 2018-2025
  • Figure 8.11: Netherlands Digital Biomarkers Market, By Settings, 2018-2025
  • Figure 8.12: Germany Digital Biomarkers Market, 2018-2025
  • Figure 8.13: Germany Digital Biomarkers Market (by Setting), 2018-2025
  • Figure 8.14: U.K. Digital Biomarkers Market, 2018-2025
  • Figure 8.15: U.K. Digital Biomarkers Market (by Setting), 2018-2025
  • Figure 8.16: France Digital Biomarkers Market, 2018-2025
  • Figure 8.17: France Digital Biomarkers Market (by Setting), 2018-2025
  • Figure 8.18: Spain Digital Biomarkers Market, 2018-2025
  • Figure 8.19: Spain Digital Biomarkers Market (by Setting), 2018-2025
  • Figure 8.20: Italy Digital Biomarkers Market, 2018-2025
  • Figure 8.21: Italy Digital Biomarkers Market (by Setting), 2018-2025
  • Figure 8.22: Russia Digital Biomarkers Market, 2018-2025
  • Figure 8.23: Russia Digital Biomarkers Market (by Setting), 2018-2025
  • Figure 8.24: Belgium Digital Biomarkers Market, 2018-2025
  • Figure 8.25: Sweden Digital Biomarkers Market, 2018-2025
  • Figure 8.26: Denmark Digital Biomarkers Market, 2018-2025
  • Figure 8.27: Norway Digital Biomarkers Market, 2018-2025
  • Figure 8.28: Asia-Pacific Digital Biomarkers Market, 2018-2025
  • Figure 8.29: Factors Influencing Digital Biomarkers Market in Asia-Pacific
  • Figure 8.30: China Digital Biomarkers Market, 2018-2025
  • Figure 8.31: China Digital Biomarkers Market (by Setting), 2018-2025
  • Figure 8.32: Japan Digital Biomarkers Market, 2018-2025
  • Figure 8.33: Japan Digital Biomarkers Market (by Setting), 2018-2025
  • Figure 8.34: South Korea Digital Biomarkers Market, 2018-2025
  • Figure 8.35: South Korea Digital Biomarkers Market (by Setting), 2018-2025
  • Figure 8.36: India Digital Biomarkers Market, 2018-2025
  • Figure 8.37: India Digital Biomarkers Market (by Setting), 2018-2025
  • Figure 8.38: Australia Digital Biomarkers Market, 2018-2025
  • Figure 8.39: Australia Digital Biomarkers Market (by Setting), 2018-2025
  • Figure 8.40: Singapore Digital Biomarkers Market, 2018-2025
  • Figure 8.41: Latin America Digital Biomarkers Market, 2018-2025
  • Figure 8.42: Factors Influencing Digital Biomarkers Market in Latin America
  • Figure 8.43: Brazil Digital Biomarkers Market, 2018-2025
  • Figure 8.44: Brazil Digital Biomarkers Market (by Setting), 2018-2025
  • Figure 8.45: Mexico Digital Biomarkers Market, 2018-2025
  • Figure 8.46: Mexico Digital Biomarkers Market (by Setting), 2018-2025
  • Figure 8.47: Rest-of-the-World Digital Biomarkers Market, 2018-2025
  • Figure 8.48: Factors Influencing Digital Biomarkers Market in Rest-of-the-World
  • Figure 8.49: Saudi Arabia Digital Biomarkers Market, 2018-2025
  • Figure 8.50: Saudi Arabia Digital Biomarkers Market (by Setting), 2018-2025
  • Figure 8.51: UAE Digital Biomarkers Market, 2018-2025
  • Figure 8.52: UAE Digital Biomarkers Market (by Setting), 2018-2025
  • Figure 8.53: Israel Digital Biomarkers Market, 2018-2025
  • Figure 8.54: Israel Digital Biomarkers Market (by Setting), 2018-2025
  • Figure 8.55: South Africa Digital Biomarkers Market, 2018-2025
  • Figure 8.56: South Africa Digital Biomarkers Market (by Setting), 2018-2025
  • Figure 9.1: Total Number of Companies Profiled
  • Figure 9.2: ActiGraph, LLC.: SWOT Analysis
  • Figure 9.3: Akili Interactive Labs: SWOT Analysis.
  • Figure 9.4: AliveCor Inc.: SWOT Analysis
  • Figure 9.5: Altoida Inc.: SWOT Analysis
  • Figure 9.6: Amgen Inc: Overall Financials, 2016-2018
  • Figure 9.7: Amgen Inc. Revenue (by Region), 2016-2018
  • Figure 9.8: Amgen Inc R&D Expenditure, 2016-2018
  • Figure 9.9: Amgen Inc: SWOT Analysis
  • Figure 9.10: Bayer Inc.: Overall Financials, 2016-2018
  • Figure 9.11: Bayer Inc: Revenue (by Segment), 2016-2018
  • Figure 9.12: Bayer Inc: Revenue (by Region), 2016-2018
  • Figure 9.13: Bayer Inc: R&D Expenditure, 2016-2018
  • Figure 9.14: Bayer Inc: SWOT Analysis
  • Figure 9.15: Biogen Inc: Overall Financials, 2016-2018
  • Figure 9.16: Biogen: Revenue (by Region), 2016-2018
  • Figure 9.17: Biogen: R&D Expenditure, 2016-2018
  • Figure 9.18: Biogen Inc: SWOT Analysis
  • Figure 9.19: Eli Lilly and Company: Overall Financials, 2016-2018
  • Figure 9.20: Eli Lilly and Company: Revenue (by Segment), 2016-2018
  • Figure 9.21: Eli Lilly and Company: Revenue (by Region), 2016-2018
  • Figure 9.22: Eli Lilly and Company: R&D Expenditure, 2016-2018
  • Figure 9.23: Eli Lilly and Company: SWOT Analysis
  • Figure 9.24: Evidation Health: SWOT Analysis
  • Figure 9.25: Fitbit Inc.: Overall Financials, 2016-2018
  • Figure 9.26: Fitbit Inc.: Revenue (by Region), 2016-2018
  • Figure 9.27: Fitbit, Inc.: R&D Expenditure, 2016-2018
  • Figure 9.28: Fitbit Inc.: SWOT Analysis
  • Figure 9.29: GlaxoSmithKline: Overall Financials, 2016-2018
  • Figure 9.30: GlaxoSmithKline: Revenue (by Business Segments), 2016-2018
  • Figure 9.31: GlaxoSmithKline: Revenue (by Region), 2016-2018
  • Figure 9.32: GlaxoSmithKline: Research and Development Investment, 2016-2018
  • Figure 9.33: GlaxoSmithKline: SWOT Analysis
  • Figure 9.34: HumanAPI: SWOT Analysis
  • Figure 9.35: Happify: SWOT Analysis
  • Figure 9.36: IXICO plc: Overall Financials, 2016-2018
  • Figure 9.37: IXICO plc: Revenue (by Region), 2016-2018
  • Figure 9.38: IXICO plc: R&D Expenditure, 2016-2018
  • Figure 9.39: IXICO plc: SWOT Analysis
  • Figure 9.40: Neurotrack Technology: SWOT Analysis
  • Figure 9.41: Novartis AG: Overall Financials, 2016-2018
  • Figure 9.42: Novartis AG: Revenue (by Segment), 2016-2018
  • Figure 9.43: Novartis AG: Revenue (by Region), 2016-2018
  • Figure 9.44: Novartis AG, 2016-2018
  • Figure 9.45: Novartis AG: SWOT Analysis
  • Figure 9.46: Pfizer,Inc: Overall Financials, 2016-2018
  • Figure 9.47: Pfizer Inc: Revenue (by Segment), 2016-2018
  • Figure 9.48: Pfizer Inc: Revenue (by Region), 2016-2018
  • Figure 9.49: Pfizer Inc.: R&D Expenditure, 2016-2018
  • Figure 9.50: Pfizer Inc.: SWOT Analysis
  • Figure 9.51: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
  • Figure 9.52: F. Hoffmann-La Roche Ltd: Overall Financials, 2016-2018
  • Figure 9.53: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2016-2018
  • Figure 9.54: F. Hoffmann-La Roche Ltd: Revenue Split for Diagnostics, 2016-2018
  • Figure 9.55: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2016-2018
  • Figure 9.56: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2016-2018
  • Figure 9.57: F. Hoffmann-La Roche Ltd: SWOT Analysis
  • Figure 9.58: Sanofi: Overall Financials, 2016-2018
  • Figure 9.59: Sanofi: Revenue (by Business Segments), 2016-2018
  • Figure 9.60: Sanofi: Revenue (by Region), 2016-2018
  • Figure 9.61: Sanofi: Research and Development (R&D) Investment, 2016-2018
  • Figure 9.62: Sanofi: SWOT Analysis
  • Figure 9.63: Takeda Pharmaceuticals: Overall Financials, 2016-2018
  • Figure 9.64: Takeda Pharmaceuticals: Revenue (by Region), 2016-2018
  • Figure 9.65: Takeda Pharmaceuticals: R&D Expenditure, 2016-2018
  • Figure 9.66: Takeda Pharmaceuticals: SWOT Analysis
  • Figure 9.67: Verily Life Science LLC: SWOT Analysis
Back to Top